Media & news

The Annual General Meeting of Nobel Biocare approves all proposals of the Board of Directors

Nobel Biocare Holding AG’s Annual General Meeting today endorsed all proposals put forward by the Board of Directors.

Among others, the Annual General Meeting approved a dividend of CHF 0.20 gross per registered share of CHF 0.40 nominal value. The dividend will be paid on 8 April 2013 (ex-dividend day: 3 April 2013; record date: 5 April 2013) in a shareholder-friendly way without deduction of withholding tax.

All Board members proposed for re-election were re-elected: Daniela Bosshardt-Hengartner, Raymund Breu, Edgar Fluri, Michel Orsinger, Juha Räisänen, Oern Stuge, Rolf Watter and Georg Watzek.

Franz Maier was elected as a new Board member.

According to the by-laws, all Board members have been elected for a one-year term.

At the first board meeting following the Annual General Meeting, Rolf Watter was re-elected Chairman of the Board and Raymund Breu was re-elected Vice-Chairman of the Board. The Board committees will be chaired by Oern Stuge (Innovation and Technology), Edgar Fluri (Audit), Juha Räisänen (Operations and Process Excellence), Rolf Watter (Nomination and Compensation) and Michel Orsinger (Strategy (newly established committee)).

KPMG, Zurich, has been re-elected as auditors for the financial year 2013.

The next Annual General Meeting of the shareholders will be convened on March 26, 2014.

Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.